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Context: Subclinical and clinical complications emerge early in type 1 diabetes (T1D) and may be
associated with obesity and hyperglycemia.
Objective: Test how longitudinal “weight-glycemia” phenotypes increase susceptibility to different
patterns of early/subclinical complications among youth with T1D.
Design: SEARCH for Diabetes in Youth observational study.
Setting: Population-based cohort.
Participants: Youth with T1D (n 5 570) diagnosed 2002 to 2006 or 2008.
MainOutcomeMeasures: Participants were clustered based on longitudinal bodymass index z score
andHbA1c fromabaseline visit and 51 year follow-up visit (meandiabetes duration: 1.46 0.4 years and
8.2 6 1.9 years, respectively). Logistic regression modeling tested cluster associations with seven
early/subclinical diabetes complications at follow-up, adjusting for sex, race/ethnicity, age, and duration.
Results: Four longitudinal weight-glycemia clusters were identified: The Referent Cluster (n 5 195,
34.3%), theHyperglycemiaOnlyCluster (n5 53, 9.3%), theElevatedWeightOnlyCluster (n5 206, 36.1%),
and the ElevatedWeightWith Increasing Hyperglycemia (EWH) Cluster (n5 115, 20.2%). Comparedwith
the Referent Cluster, the Hyperglycemia Only Cluster had elevated odds of dyslipidemia [adjusted odds
ratio (aOR) 2.22, 95% CI: 1.15 to 4.29], retinopathy (aOR 9.98, 95% CI: 2.49 to 40.0), and diabetic kidney
disease (DKD) (aOR 4.16, 95%CI: 1.37 to 12.62). The EWHCluster had elevated odds of hypertension (aOR
2.18, 95%CI: 1.19 to4.00), dyslipidemia (aOR2.36, 95%CI: 1.41 to3.95), arterial stiffness (aOR2.46, 95%CI:
1.09 to 5.53), retinopathy (aOR 5.11, 95% CI: 1.34 to 19.46), and DKD (aOR 3.43, 95% CI: 1.29 to 9.11).
Abbreviations: aOR, adjusted odds ratio; BMI, body mass index; BMIz, body mass index z
score; CVD, cardiovascular disease; DAA, diabetes autoantibody; DEPS-R, Diabetes Eating
Problem Survey Revised; DKD, diabetic kidney disease; EWH, Elevated Weight With
Increasing Hyperglycemia; HDL, high-density lipoprotein; T1D, type 1 diabetes.
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Conclusions: Weight-glycemia phenotypes show different patterns of complications, particularly
markers of subclinical macrovascular disease, even in the first decade of T1D. (J Clin Endocrinol
Metab 104: 6003–6016, 2019)
Subclinical and clinical complications emerge early intype 1 diabetes (1). In youth and adolescents, multiple
studies have shown that the risk for these outcomes is
associated with glycemic control as measured by HbA1c
(1–3). However, the rising prevalence of overweight and
obesity is a recently emerging problem in the clinical care
of type 1 diabetes (4–6). Studies suggest that obesity in the
setting of type 1 diabetes can contribute to adverse car-
diovascular disease (CVD) outcomes and microvascular
complications in adults with long-standing diabetes (7–9).
There are gaps in the current understanding of how
excess adiposity and degrees of suboptimal glycemic
control jointly contribute to the emergence of early and
subclinical diabetes complications, including both mac-
rovascular and microvascular outcomes, among youth
and young adults in the first decade of having diabetes.
This information is critical given shifts in the epidemiology
of overweight and obesity within this patient population
and the potential for intensive insulin therapy to induce
weight gain (10), which may warrant a more flexible and
integrated clinical approach that considers both weight
and glycemic control for identifiable patient subgroups.
Although the association between weight status and
glycemic control among youth and adolescents have been
studied in the first few years of disease (11, 12), few studies
have characterized the coevolution of these outcomes over a
longer disease duration, and particularly outside of the
partial remission, or “honeymoon” period, when blood
glucose management is particularly challenging (13). There-
fore, we employed a data-driven approach to capture the
major patterns of longitudinal exposure of both weight
status and glycemic control. The first objective of this study
was to identify the main longitudinal “weight-glycemia”
phenotypes of established type 1 diabetes, or clusters of
youth and young adults with type 1 diabetes showing similar
weight status and glycemic control measures collected at two
time-points: a baseline . 1 year after diabetes onset and a
follow-up visit at a mean of 8 years disease duration. The
second objective was to test how the longitudinal weight-
glycemia phenotypes of type 1 diabetes were associated with
different subclinical and early complications, or combina-
tions thereof, measured at the follow-up visit.
Materials and Methods
Participants
Individuals diagnosed with diabetes before 20 years of age
were identified by the SEARCH for Diabetes in Youth study
through a population-based registry network at five sites in the
United States (South Carolina; Cincinnati, Ohio, and sur-
rounding counties; Colorado, with southwestern American
Indian sites; Seattle, Washington, and surrounding counties;
and Kaiser Permanente, Southern California membership in
seven counties). Individuals who received a new diagnosis of
type 1 diabetes (T1D) in 2002 to 2006 or 2008 were invited to
complete a baseline SEARCH visit to measure risk factors for
diabetes complications. In 2011 to 2015, participants with$ 5
years diabetes duration who had previously completed a
baseline visit were invited to participate in a follow-up visit, at
which diabetes risk factors and early diabetes-related compli-
cations and comorbidities were assessed. The distribution of
demographic, metabolic, and socioeconomic characteristics of
participants who completed the follow-up visit were similar to
that of the larger SEARCH registry population (1). The study
was approved by institutional review boards with jurisdiction,
and the parent, adolescent or young adult, or both provided
consent or assent for all participants.
Inclusion criteria for the present analysis consisted of incident
cases of type 1 diabetes between 2002 and 2006 and 2008 who
attended the SEARCH baseline and follow-up “cohort” visit
(n 5 2869). Diabetes type was based on an etiological classifi-
cation using diabetes autoantibodies (DAAs) or estimated insulin
sensitivity score (euglycemic clamp-validated equation including
waist circumference, HbA1c, and triglyceride levels) measured at
the baseline visit (14). Youth includedwere those whowereDAA
positive and insulin sensitive, DAA positive and insulin resistant,
DAA negative and insulin sensitive, DAA unknown and insulin
sensitive, and DAA positive and unknown insulin sensitivity
status. Participants were excluded if they were missing measures
of body mass index z score (BMIz) or HbA1c at the baseline or
follow-up visit (n 5 1106) or if the baseline visit occurred ,
12 months after a T1D diagnosis (n 5 1193) to remove non-
informative variability or within-person instability in baselines
measure that may occur in the first year following diagnosis
(Fig. 1). The latter exclusion cut-off was selected to ensure
participants were not in partial remission, or the “honeymoon
period,” at their baseline visit based on data showing that more
than one-half and one-third of youth . 5 years are classified as
being in remission at 3 and 6 months, respectively, based on
insulin needs (U/kg/dose) (15) as well as longitudinal patterns in
HbA1c, insulin dose, and C-peptide levels in the first 12 months
of disease (16). Compared with individuals included in the
analysis, excluded participants showed a lower mean age,
HbA1c, and pump use at baseline (P, 0.05), with no important
differences in BMIz or age at diagnosis. There were also no
substantial differences in age, BMIz, or HbA1c between these
groups at the follow-up visit.
Research visits
Trained, certified research staff administered questionnaires,
made measurements, and obtained blood samples at the in-person
baseline and follow-up research visits in accordance with stan-
dardized study protocols (available at www.searchfordiabetes.org).
Participants (or parents, for younger participants) self-reported date
of birth, sex, race, ethnicity, highest parental education, annual
household income, and type of health insurance. For reporting of
race and ethnicity, US census methods (17) were used that
provided a series of fixed race and ethnicity categories as well as an
“other” option for the self-report by parent or participant,
depending on age. These were further categorized into “non-
Hispanic white” and “minority” racial/ethnic groups, including
Hispanic (regardless of race), non-Hispanic black, American In-
dian, Asian/Pacific Islander, and other/multiple race/ethnicities.
Education and income were self-reported. Highest education by
either parent was classified as less than high school degree,
high school graduate, some college through associate degree,
and bachelor’s degree or more. Annual household income was
classified as .$75,000, $50,000 to 75,000, $25,000 to
49,999, and ,$25,000. Date of diagnosis obtained from
medical records was used to calculate age of diagnosis and
diabetes duration at both visits. BMI was defined as weight
(kg) divided by height (m2) and converted to a z score (18).
Weight status was classified as underweight (mean BMIz less
than 21.64), normal weight (mean BMIz 21.64 to ,1.04),
overweight (mean BMIz 1.04 to ,1.64), and obesity (mean
BMIz $1.64), corresponding to ,5th, 5 to ,85th, 85th to
,95th, and $95th percentile for age and sex, respectively
(19). Waist circumference used the National Health and
Nutrition Examination Survey protocol and was used to
calculate waist-to-height ratio (20). A blood draw occurred
after an 8-hour overnight fast, and medications, including
short-acting insulin, were withheld the morning of the visit.
Blood samples were obtained and analyzed for HbA1c, glu-
cose, lipids, creatinine, and cystatin C at the central laboratory
using established protocols (Northwest Lipid Metabolism and
Diabetes Research, Seattle, WA). Samples were shipped from
clinical centers to the central laboratory. HbA1c was mea-
sured in whole blood with an automated nonporous ion-
exchange high-performance liquid chromatography system
(model G-7; Tosoh Bioscience, Montgomeryville, PA).
Outcome measures
The main outcomes for the study included seven early or
subclinical diabetes complications measured at the follow-up
visit. Definitions of outcomes complications were consistent
with previous SEARCH studies (1, 21, 22).
For the outcome of hypertension, the mean of three systolic
and diastolic blood pressure levels was obtained using an aneroid
manometer after at least 5 minutes of rest. Hypertension was
defined based on 2017 American Academy of Pediatrics Clinical
Practice Guidelines (23) as blood pressure $130/80 mm Hg
or $95th percentile for ages ,13 years or the use of antihy-
pertensive medication. The outcome of dyslipidemia was defined
to be consistent with previous SEARCH studies (21) following
recommendations for children with type 1 diabetes (24, 25)
and included high-density lipoproteins (HDLs) dyslipidemia
(HDL ,35 mg/dL) and non-HDL dyslipidemia (computed as
total cholesterol 2 HDL-cholesterol .130 mg/dL), or use of a
lipid-lowering medication. Arterial stiffness was measured with
the SphygmoCor-Vx device (AtCor Medical, Lisle, IL) and de-
fined as a carotid-femoral pulse wave velocity $90th percentile
compared with control participants of the SEARCH CVD an-
cillary study (26). Diabetic retinopathy was assessed with 45°
color digital fundus images taken with a nonmydriatic camera
(Visucam Pro N, Carl Zeiss Meditech, Dublin, CA) and centered
on the disc andmacula of both eyes. Photosmasked to all clinical
characteristics were graded by the Wisconsin Ocular Epidemi-
ology Reading Center. Diabetic retinopathy was defined
as mild, moderate, or proliferative retinopathy in at least one
eye (27). Diabetic kidney disease (DKD) was defined as the
presence of microalbuminuria (urine albumin-to-creatinine
ratio $30 mg/mg of creatinine) or low glomerular filtration rate
(,60 mL/min/1$73 m2 as estimated by the CKD-EPI creatinine
equation using serum creatinine and cystatin C) (28). Peripheral
neuropathy was defined as a score .2 on the Michigan Neu-
ropathy Screening Instrument (29). Cardiovascular autonomic
neuropathy was assessed by heart rate variability using the
SphygmoCor-Vx device (AtCor Medical). Electrocardiographic
R-R intervalsmeasured in a supine positionwere used to estimate
five heart rate variability indices: the SD of the intervals, root
mean square differences of successive intervals, normalized high-
frequency power, normalized low-frequency power, and the low-
to-high frequency ratio. Cardiovascular autonomic neuropathy
was defined as abnormalities in three or more of the five indices,
based on #5th or $95th percentile (as appropriate) observed in
age- and sex-matched control participants of the SEARCH CVD
study (26).
Other measures
Participants reported insulin regimen, classified as the use of
an insulin pump vs any combination of multiple daily injection.
Self-reported frequency of self-monitoring of blood glucose was
categorized as ,1, 1 to 3, and .3 times per day. History of
severe hypoglycemia (defined as any episode requiring the help
of another person) or diabetic ketoacidosis in the past 6 months
were self-reported. Disordered eating behaviors was assessed
with the Diabetes Eating Problem Survey Revised (DEPS-R)
(30) at the follow-up visit. The DEPS-R survey assesses be-
haviors such as skipping insulin or keeping blood sugars high to
lose weight as well as feelings toward the relative priorities of
losing weight and taking care of one’s diabetes. Higher scores
indicate increased disordered eating behaviors, with a cut-off
score of 20 or higher recommended for further clinical evalu-
ation for disordered eating behaviors (31). To directly address
insulin omission as a strategy to manage weight gain, affir-
mative responses from Item 17 (i.e., answered “yes” in response
Figure 1. Participant flow diagram.
to the question, “I take less insulin than I should”) from the
DEPS-R were also individually analyzed and presented.
Statistical methods
Participants were clustering using k-means clustering for
joint longitudinal data applied to BMIz and HbA1c values
from baseline and follow-up to derive clusters of homogenous
subgroups within a larger heterogeneous population (32, 33).
Data from the interim follow-up visits (i.e., the 12-, 24-, and
60-month follow-up examinations) were not used due to
variable degrees of sparsity. In this procedure, participants
who are homogenous in their BMIz and HbA1c measures at
both time-points are clustered together. BMIz and HbA1c
measures were first normalized, and participants were clus-
tered using the KmL3D package (34) in R using Euclidean
distance. Briefly, k-means is an expectation-maximization
algorithm: the center of each cluster is determined as the
mean of data points within the cluster in the expectation step,
then data points are reassigned to the nearest cluster center in
the maximization step. These two steps are repeated until the
clusters no longer change. Any number of methods can be used
to provide the starting cluster assignments thereby initializing
the process; the kml3d procedure alternates through different
initialization methods and chooses the partition with the most
stability (34). To obtain optimal solutions, we estimated
cluster solutions 100 times each for between four- and nine-
cluster solutions, exploring this as the literature suggests there
are multiple longitudinal patterns of weight and glycemia, but
we do not know how many accurately represents the major
phenotypes (32). The Calinski-Harabasz criterion (35) was
used to evaluate the various trajectory solutions and identify
the optimal number of weight-glycemia longitudinal clusters.
The Calinski Criterion is a relative metric that measures the
ratio of the between-group variance relative to the within-
group variance. The optimal clustering solution maximizes
this ratio, representing the most compact and well-separated
clusters (32, 33, 35).
Clusters were named based on primary exposure to elevated
weight (i.e., elevated BMIz) or hyperglycemia (i.e., elevated
HbA1c) at both time-points, relative to each other. The cluster
with BMIz and HbA1c measures closest to clinical targets was
selected as the Referent Cluster (13). This method of cluster
nomenclature was selected to facilitate cluster-level phenotypic
interpretation and comparisons thereof.
Cluster characteristics and associations
with outcomes
The proportion of early or subclinical diabetes complica-
tions, sociodemographic characteristics, and clinical care cor-
relates of each cluster were summarized using descriptive
statistics. Overall tests of independence across clusters were
carried out using ANOVA for continuous features and x2 tests
for categorical features. Typically, Fisher’s exact tests would be
used to obtain the exact hypergeometric distribution for a 23 2
contingency table with low counts. However, because our ta-
bles have four rows (for four clusters), obtaining the exact
distribution is computationally intensive. Therefore, we use a x2
test where the distribution is approximated using the Monte
Carlo method with 9999 random samples. In each sample, the
feature categories are permuted, and the test statistic is com-
puted (36). We accounted for multiple comparisons in the
overall tests of difference using Bonferroni adjustment. If the
overall test of difference was statistically significant, pairwise
comparisons were performed for all clusters against the Ref-
erent Cluster.
Logistic regression modeling was used to test how each
weight-glycemia subgroup was associated with early or sub-
clinical diabetes complications. Each outcome was modeled
independently as a binary outcome, adjusting for minimum
confounders: sex, race/ethnicity (non-Hispanic white vs all
others), age, and diabetes duration at follow-up. Small cell sizes
prohibited extensive adjustment models. An additional model
tested the association of the clusters with the probability of
having two or more early or subclinical complications.
All P-values were evaluated at the 0.05 significance level.
Data analyses were performed using the statistical analysis
software package R version 3.4.1 and SAS 9.4 (SAS Institute,
Cary, NC).
Results
The final sample included 570 youth with established
T1D, 53.5% female and 70.9% non-Hispanic white
race/ethnicity, with mean age at diagnosis of 9.7 6 4.1
years and mean age at follow-up of 17.96 4.6 years. The
baseline visit and follow-up visit occurred at approxi-
mately 1.46 0.4 years and 8.26 1.9 years after diabetes
diagnosis, respectively.
Four longitudinal weight-glycemia clusters were iden-
tified over a mean of 8 years disease duration (Fig. 2;
Table 1). The Referent Cluster (n5 195, 34.3%) showed
stable low BMIz and fair glycemic control at both time
points. The Hyperglycemia Only Cluster (n 5 53, 9.3%)
showed low BMIz with stable high HbA1c at both time
points, where mean HbA1c was 10.8% 6 1.9% (93 6
21 mmol/mol) at baseline and 11.4% 6 1.9% (100 6
20 mmol/mol) at follow-up. The Elevated Weight Only
Cluster (n5 206, 36.1%) showed elevated BMIz, with only
48.5% and 36.9% of individuals being classified as normal
weight at baseline and follow-up, respectively, and moder-
ate HbA1c levels at both time points [HbA1c of 7.6% 6
1.1% (60 6 12 mmol/mol) and 8.1% 6 1.0% (65 6
11 mmol/mol) at baseline and follow-up, respectively]. The
Elevated Weight with Increasing Hyperglycemia Cluster
(n 5 115, 20.2%) showed high BMIz at both time points,
with only approximately 30% to 32% of individual being
classified as normal weight across time, andwith increasing
HbA1c over time [mean HbA1c 8.4% 6 1.5% (67 6
15 mmol/mol) and 11.2%6 1.4% (996 15mmol/mol) at
baseline and follow-up, respectively]. A three-dimensional,
interaction plot of the longitudinal weight-glycemia clusters
is shown in the data repository (37).
The longitudinal weight-glycemia clusters showed
significant differences in sociodemographic characteris-
tics and aspects of type 1 diabetes clinical care (Table 2).
Compared with the Referent Cluster, the Hyperglycemia
Only Cluster and the Elevated Weight with Increasing
Hyperglycemia Cluster comprised a significantly lower
proportion of non-Hispanic white youth and reported
lower levels of parental education, household income,
and use of private health insurance (all P, 0.05). These
clusters also had a lower proportion of pump users and
individuals who checked glucose levels four or more
times per day (all P , 0.05). There were no significant
differences in sex, age, or diabetes duration at follow-
up. Finally, there were significant differences in self-
reported eating behaviors. The Elevated Weight with
Increasing Hyperglycemia Cluster was associated with
greater disordered eating behaviors at the follow-up
visit, including the highest prevalence of self-reported
insulin omission (35.9% compared with 15.1% in the
Reference Cluster; Table 2).
The prevalence of dyslipidemia, retinopathy, and DKD
was significantly different across clusters (all P , 0.05;
Table 2). After adjustment for sex, race/ethnicity, age,
and diabetes duration at follow-up, and compared with
the Referent Cluster, the Hyperglycemia Only Cluster
had elevated odds of dyslipidemia (OR 2.22, 95% CI:
1.15 to 4.29], retinopathy (OR 9.98, 95% CI: 2.49 to
40.0), and DKD (OR 4.16, 95% CI: 1.37 to 12.62)
(Table 3). The Elevated Weight with Increasing Hy-
perglycemia Cluster had elevated odds of hypertension
(OR 2.18, 95% CI: 1.19 to 4.00), dyslipidemia (OR
2.36, 95% CI: 1.41 to 3.95), arterial stiffness (OR 2.46,
95% CI: 1.09 to 5.53), retinopathy (OR 5.11, 95% CI:
1.34 to 19.46), and DKD (OR 3.43, 95% CI: 1.29 to
9.11). Compared with the Referent Cluster, the Elevated
Weight Only Cluster was not significantly associated
with any of the early or subclinical diabetes complica-
tions. There were no significant interactions by sex or
race/ethnicity.
TheHyperglycemiaOnly Cluster and ElevatedWeight
with Increasing Hyperglycemia Cluster reported 1.1 6
1.0 and 1.2 6 1.1 total early or subclinical diabetes
complications, compared with 0.7 6 0.8 in the Referent
Cluster (P , 0.0001). In adjusted models, the Hyper-
glycemia Only Cluster had 2.17 times higher odds than
the Reference Cluster of having two ormore co-occurring
early or subclinical diabetes complications (OR 2.2, 95%
CI: 1.01 to 4.68). The Elevated Weight with Increasing
Hyperglycemia Cluster had 3.4 times higher odds of
having two or more co-occurring complications (OR 3.4,
95% CI: 1.86 to 6.21).
Discussion
We demonstrate here that there are subgroups of youth
and young adults with established type 1 diabetes sharing
longitudinal phenotypes defined by patterns in weight
status and glycemic control over the very early natural
history of type 1 diabetes. Phenotypic clusters showed
different associations with early or subclinical diabetes
complications at a mean of 8 years’ diabetes duration.
We focus our discussion on the longitudinal weight-
glycemia phenotypes first, and then turn to their asso-
ciations with complications.
The four clusters showed clinically significant differ-
ences in mean BMIz and HbA1c measures over time,
providing phenotypes that integrate information from
both key clinical parameters. Only 34% of the sample
Figure 2. Longitudinal weight glycemia phenotypes in the SEARCH for Diabetes in Youth Study. Clusters were derived from baseline and follow-up
measures of BMIz and HbA1c over a mean of 8.2 y. Clusters were named based on their main exposure, where high HbA1c is denoted by “Hyperglycemia”
(H) and elevated BMIz is denoted by “Adiposity” (A). Four clusters were identified: The Referent Cluster (n 5 195, 34.2%), the Hyperglycemia Only Cluster (n
5 53, 9.3%), the Elevated Weight Only Cluster (n 5 206, 36.1%), and the Elevated Weight with Increasing Hyperglycemia Cluster (n 5 116, 20.4%). (A)
Scatter plot of BMIz and HbA1c, colored by cluster, at both time points. (B) Cluster trajectories of BMIz and HbA1c between baseline and follow-up visit. EW,
Elevated Weight Only Cluster; EWH, Elevated Weight with Increasing Hyperglycemia Cluster; H, Hyperglycemia Only Cluster; R, Referent Cluster.
doi: 10.1210/jc.2019-00734 6007
was captured in the Referent Cluster, suggesting that a
relatively small proportion of youth and young adults
with type 1 diabetes have BMIz and HbA1c measures
that meet or approach clinical targets for both weight
status and glycemic control. Although the Hyperglyce-
mia Only Cluster was the smallest cluster, comprising
9% of the sample, this subgroup distinguished itself by
significant hyperglycemia at both time points. By con-
trast, the Elevated Weight Only Cluster and the Elevated
Weight with Increasing Hyperglycemia Cluster com-
prised approximately 50% of the overall sample. Despite
data showing that risk for obesity increases in people
with type 1 diabetes as they age (38), the clusters showed
relatively consistent measures of elevated BMIz from
Table 1. Weight and Glycemia at the Baseline and Follow-Up Visit Across the Longitudinal Weight-Glycemia
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BMIz 0.54 (1.07) 20.36 (0.85) 20.21 (1.02) 1.12 (0.59)a 1.36 (0.67)a ,0.0001




Underweight 15 (2.6) 10 (5.2) 5 (9.4) 0 (0.0)a 0 (0.0)a
Normal weight 364 (63.9) 183 (93.9) 46 (86.8) 100 (48.5)a 35 (30.2)a
Overweight 110 (19.3) 2 (1.0) 2 (3.8) 63 (30.6)a 43 (37.1)a




Adequate 192 (33.7) 72 (36.9) 1 (1.9)a 89 (43.2) 30 (25.9)a
Fair 244 (42.8) 103 (52.8) 7 (13.2)a 93 (45.2) 41 (35.3)a
Poor 121 (21.2) 20 (10.2) 33 (62.3)a 24 (11.7) 44 (37.9)a




BMIz 0.64 (0.97) 20.11 (0.72) 20.27 (1.07) 1.21 (0.54)a 1.30 (0.61)a ,0.0001




Underweight 11 (1.9) 7 (3.6) 4 (7.6) 0 (0.0)a 0 (0.0)a
Normal weight 344 (60.4) 185 (94.9) 46 (86.8) 76 (36.9)a 37 (31.9)a
Overweight 139 (24.4) 3 (1.5) 3 (5.7) 85 (41.3)a 48 (41.4)a




Adequate 85 (14.9) 36 (18.5) 1 (1.9)a 48 (23.3)d 0 (0.0)a
Fair 213 (37.4) 90 (46.2) 4 (7.6)a 117 (56.8)d 2 (1.7)a
Poor 225 (39.5) 69 (35.4) 26 (49.1)a 41 (19.9)d 89 (76.7)a
Very poor 47 (8.3) 0 (0.0) 22 (41.5)a 0 (0.0)d 25 (21.6)a
Data aremean6 SD (continuous), or n (%) (categorical). Overall P values are from x2, Fisher exact tests and ANOVA, as appropriate. Bonferroni correction
was applied. Pairwise comparisons were performed for significant variables using the Referent Cluster as the referent group.
aPairwise P , 0.05.
bWeight status defined based on BMIz. Underweight was defined as BMIz less than 21.64 corresponding to the 5th percentile for age and sex.
Normal weight was defined as BMIz at least 21.64 and , 1.04, corresponding to $ 5th and , 85th percentile for age and sex. Overweight was
defined as BMIz$ 1.04 and, 1.64, corresponding to$ 85th percentile and, 95th percentile for age and sex. Obesity was defined as BMIz$ 1.64
corresponding to $ 95th percentile for age and sex.
cGlycemic control: adequate [HbA1c, 58mmol/mol (7.5%)], fair [HbA1c$ 58 and, 75mmol/mol ($ 7.5 and, 9.0%)]; poor [HbA1c$ 75 and, 108
mmol/mol ($9.0% and ,12.0%)]; very poor [HbA1c . 108 mmol/mol ($12.0%)].
dPairwise P , 0.0001.
study. In a younger population and over a shorter du-
ration, the findings from the current study appear to
be better-suited to illuminate the effects of obesity as
they compound complications of hyperglycemia; this
remains a critical insight as the incidence of diabetes-
related complications has recently rebounded among
young adults ages 18 to 44 years with type 1 diabetes
(45). In addition, these data also elude to physiologic
differences between the Elevated Weight Only Cluster
and the Elevated Weight with Increasing Hyperglycemia
Cluster early in disease duration that may warrant more
investigation toward optimizing therapy for obesity in
type 1 diabetes. Compared with the subgroup with ele-
vated weight and increasing hyperglycemia, the Elevated
Weight Only subgroup showed lower mean waist cir-
cumference, lower mean waist-to-height ratio, and lower
mean insulin doses with improved glycemic control and a
lower prevalence of dyslipidemia at the follow-up visit
(all P , 0.05). One interpretation of these differences
is that weight gain in T1D that coincides with lower
indices of insulin resistance may be protective against the
development of complications. Confirmation of these
findings may lend evidence toward using distinct ther-
apeutic approaches such as metformin (46) to optimize
early outcomes among youth with type 1 diabetes who
show weight gain with markers of increased insulin re-
sistance in the first decade after diagnosis.
In logistic regression modeling, the Elevated Weight
with Increasing Hyperglycemia Cluster had a higher risk
of subclinical macrovascular complications including
hypertension, and dyslipidemia and arterial stiffness, in
addition to the microvascular complications seen in the
Hyperglycemia Only Cluster, a worrisome finding given
the elevated risk for adverse events in this population (3).
A notable finding is that this subgroup showed compa-
rable or worse outcomes at the follow-up visit compared
with the Hyperglycemia Only Cluster, the subgroup
marked by sustained high HbA1c, despite having a
significantly lower HbA1c at baseline.
The pattern in which BMI accelerates the worsening of
CVD status, despite lower relative exposure to glycemia,
is reminiscent of data from the Diabetes Control and
Complications Trial and corresponding Epidemiology
of Diabetes Interventions and Complications cohort
showing that the incident rate of total CVD events among
individuals who received intensive insulin therapy and
gained the most weight approximated the rate of those
who did not receive intensive insulin therapy after 20
years of follow-up (7). The current study may be inter-
preted as a corroboration of that pattern in a younger
population with earlier disease duration. In addition, the
findings are consistent with previous SEARCH data
showing that individuals with adverse metabolic risk
childhood onward. Moreover, neither age nor disease 
duration were significantly different across clusters at the 
follow-up visit, suggesting that the weight-glycemia phe-
notypes do not appear to be age- or duration-driven sub-
groups, although this finding may also be attributed to 
limited variability in the study population.
Our study was not designed to disentangled contri-
bution of adiposity vs hyperglycemia to the emergence 
of early or subclinical complications of diabetes, but to 
provide insight to their combined real-world effects on 
early markers for ensuing vascular outcomes. At the 
cluster level, we found a disparity in the relative risk 
for adverse outcomes across the longitudinal weight-
glycemia phenotypes. Subgroups with sustained poor or 
worsening glycemic control showed striking rates of 
microvascular complications at the follow-up visit, 
particularly when compared with the referent subgroup. 
For example, 15% of the Hyperglycemia Cluster and 
7% of the Elevated Weight with Increasing Hypergly-
cemia Cluster had retinopathy compared with 2% in the 
Referent Cluster, whereas the prevalence of DKD in 
these subgroups exceeded 15% compared with just 
4.0% in the Referent Cluster. This pattern adds to 
existing literature showing that the emergence of mi-
crovascular complications of type 1 diabetes is related 
to glycemic control (2, 39).
We did not find differences in the risk of peripheral or 
autonomic neuropathy across clusters, despite previous 
data showing these outcomes are associated with glycemic 
control and weight status (2, 8, 39, 40). Inconsistencies 
with previous studies may reflect differences in the mea-
surement of classification of outcomes. In the current 
study, the null results likely also reflect small cell sizes (n 5 
35 or 7% of the sample showed peripheral neuropathy, 
whereas n 5 63 of 12% showed cardiovascular auto-
nomic neuropathy at the follow-up visit) and diminished 
statistical power to detect smaller difference. It is also 
possible that an association may be better detected at a 
longer disease duration or older age.
Compared with the Referent Cluster, the Elevated 
Weight Only Cluster did not show an increased risk for 
different early and subclinical complications over the 
duration of follow-up in the current study. This finding is 
inconsistent with multiple studies previously showing 
obesity acts as an independent risk factor for the de-
velopment of macrovascular (41, 42) and microvascular 
complications of diabetes (8, 9, 43), as well as all-cause 
mortality (44). One possible explanation for the lack of 
association is that the effects of adiposity on the selected 
long-term complications, especially in relation to the 
Referent Cluster, may manifest after a greater duration of 
exposure or an older age and thus were not captured in 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































management, particularly those that are specific to the
youth and young adult age group. Interestingly, the latter
group also exhibited significant maladaptive eating be-
haviors to limit weight gain or induce weight loss that
could be additionally addressed to optimize both weight
and glycemia outcomes. Finally, the stratified medicine
approach also holds particular promise in light of
existing and newer noninsulin adjunctive therapies (50,
51); i.e., pharmacological interventions that have direct
impacts on both obesity and glycemic control and thus
may be most beneficial in the highest-risk subgroup. To
this end, more work is needed to extend this work to a
clinically relevant platform where risk groups can be
defined by easily measured criteria.
The current study should be considered in the context
of its limitations. The exclusion of individuals with
baseline disease duration of , 12 months diminished
sample size and may limit generalizability, where the
study population may be not representative of the full
SEARCH cohort. These exclusion criteria were judged to
be important to avoid other forms of bias that may result
from combining two phases of the early natural history of
type 1 diabetes in the baseline measures, including
misclassification bias, and based on scientific evidence
regarding the duration of partial remission in relevant
patient populations (15, 16). The resulting phenotypes
are thus representative of known challenges in glycemia
that occur after the remission period (13) rather than
differences in remission itself. Because it is not model-
based, there are no parameters to evaluate goodness-of-
fit. However, the longitudinal k-means algorithm with
parameters used in this analysis were shown to out-
perform other model based latent trajectory class ana-
lyses (52). The selection of the final number of clusters is
subjective. We used a criterion for this decision that has
been shown to perform best in nonhierarchical algo-
rithms (6). Only two time points were used in the lon-
gitudinal cluster analysis, thus interim patterns in BMIz
and HbA1c are not captured in these subgroups. Out-
comes are prevalence measures; absolute risk difference
across clusters cannot be reported. Low prevalence rates
may increase the type 2 error rate for the outcomes. The
hypertension outcome may be biased by misclassifica-
tion of youth and young adults taking antihypertensive
medications for renal protection. Sample size was not
sufficient to include additional covariates to regression
models, including markers of socioeconomic position, or
test for interactions by daily insulin dose, which could act
as an important modifier of the association between
adiposity and CVD risk factors (53). There are additional
limitations to the data, including the accuracy of self-
reported measures such as glucose monitoring frequency
and episodes of diabetic ketoacidosis. The longitudinal
profiles at baseline and follow-up visit were 10 times more 
likely to develop multiple complications than individuals 
with less adverse profiles (22), as well as data-driven 
studies in large adult cohorts showing differences in 
end-organ damage across metabolic subtypes of type 1 
diabetes (47). Findings further resonate with the increased 
prevalence of these outcomes among youth with type 2 
diabetes vs T1D, suggesting that obesity may contribute to 
the underlying pathophysiology of these outcomes (1).
Given that dual exposure to adiposity and hypergly-
cemia, as it occurs across data-driven subgroups present 
in the data, may accelerate the development of compli-
cations, particularly the subclinical macrovascular ones, 
incorporation of obesity measures as part of the clinical 
phenotype of type 1 diabetes may provide useful prognostic 
information with regards to long-term, adverse outcomes. 
As the incidence of hospitalization for major diabetes-
related complications continues to increase among young 
adults (45), future epidemiological studies should examine 
the risk associated with longitudinal BMI and HbA1c, by 
testing individual and joint models over a longer duration, 
to better characterize the associations among these risk 
factors.
The variable patterns of BMIz and HbA1c and dif-
ferential risk profiles captured from the first 8 years of 
diabetes underscore the tremendous challenges and 
complexity associated with diabetes management, as well 
as the need for clinical practice guidelines for weight 
management specifically in the setting of pediatric-onset 
type 1 diabetes (4, 13, 48). The heterogeneity across 
phenotypes with regards to clinical presentation and 
outcomes, in conjunction with multiple technologic, 
behavioral, and therapeutic options available to optimize 
or co-optimize outcomes (4), suggest that a stratified 
approach, developing treatment plans according to the 
unique needs of each subgroup, may be most appro-
priate. For example, the use of continuous glucose 
monitoring systems in the adolescent population has 
increased and shows benefit with regards to improved 
glycemic control in this age range (49). Increased use of 
such emerging diabetes technology and devices may be 
useful in mitigating hyperglycemia as well as hypogly-
cemia; hypoglycemia has been implicated as a barrier to 
exercise and a trigger for overeating, leading to weight 
gain and elevated HbA1c (48). The addition of further 
behavioral assessments across phenotypes may also 
provide rich insights into optimization of their care. For 
example, it appears that the Hypoglycemia Only Cluster 
and the Elevated Weight with Increasing Hyperglycemia 
Cluster were both associated with suboptimal diabetes 
care behaviors based on reported frequency of self-
glucose monitoring; these subgroups may benefit from 
clinical intervention to address barriers to diabetes-self
weight-glycemia clusters and their association with out-
comes was not tested in a prospective way and thus
clusters are not predictive in nature. Additional exploratory
analyses tested the predictive validity of weight-glycemia
clusters derived from baseline measures only and over-
lapping BMIz and HbA1c at the follow-up visit with
variable associations with complications; this approach
was deemed to be limited by the true variability in weight
and glycemia measures over the early history of type 1
diabetes and less informative with regards to the joint
trajectory structure inherent in the data.
There also several important strengths of this study. To
our knowledge, it is the first to identify subgroups based
on both weight and glycemia in established diabetes and
evaluate the clinical utility for predicting long-term out-
comes. The analysis takes an approach that integrates
weight with glycemic control, a paradigm that offers a
comprehensive and patient-centered approach to long-
term health issues in type 1 diabetes. Clustering BMIz
and HbA1c jointly produces a single grouping single
nominal variable (i.e., cluster) that resumes the informa-
tion contained in both sets of variables over both time
points, offering an integrated measure of exposure to
adiposity and glycemia as it occurs in real life. k-means is
nonparametric and therefore requires no prior informa-
tion for clustering (52). Capturing clinical phenotypes in
youth with type 1 diabetes reflects how clinicians work to
deliver individual care plans for patients and offers a
platform for future research toward guidelines to com-
prehensively reduce the burden of comorbid complica-
tions among young people with diabetes.
In conclusion, we found evidence of four longitudinal
weight-glycemia phenotypes of established, youth-onset
T1D in the first eight years after diagnosis in patients
with diabetes who experience different burdens of
comorbid early or subclinical complications. More
work is needed to identify therapeutic approaches tai-
lored to the needs and prognoses of each subgroup for
interventions that can be implemented early in the
natural history of type 1 diabetes.
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